It is clinically important to evaluate time course changes in symptomatic middle cerebral artery (MCA) stenotic plaques because of likely recurrence. The objective of this study is to determine whether contrast-enhanced high-resolution magnetic resonance imaging (MRI) is a feasible method for this purpose.
Introduction
Various features of plaque morphology, such as structure, composition, and volume, are targeted to identify the risk of ischemic stroke in the setting of middle cerebral artery (MCA) stenosis. Accurate evaluation of these features is relevant for the effective prediction of stroke.
Non-invasive imaging modalities, such as high-resolution magnetic resonance imaging (MRI) and ultrasonography, that target inflammatory and thrombotic components of carotid atherosclerotic plaques, can be useful in the identification of symptomatic risk of MCA plaques 1 . Recently, many investigations performed on a large number of patients have focused on the clinical significance of gadolinium (Gd) enhancement of plaques in the setting of intracranial artery stenosis, as reported by Millon et al. 2 , Skarpathiotakis et al. 3 , Qiao et al. 4 , Natori et al. 5 , and Ryu et al. 6 . These papers have described that intracranial plaque enhancement on MRI can help identify lesions responsible for an ischemic event and can potentially serve as a marker of intracranial plaque instability and stroke risk 4 . It has also been described that plaque enhancement was significantly higher in patients with symptomatic plaques in accordance with the degree of stenosis 6 . Recently, three-dimensional contrast-enhanced, high-resolution, black-blood MRI has been applied to investigate atherosclerotic lesions, which not only accurately detects atheroma burden, but also gives information regarding atheroma composition such as necrotic core, intraplaque hemorrhage, inflammation, and neovascularization 7 .
These plaque characteristics will help clinicians to estimate the vulnerability of the culprit lesion, and possibly to predict future vascular events 7, 8 . Little data so far support the prognostic value of MRI to predict future stroke.
The natural course of intracranial vessel wall lesions in patients with ischemic stroke or TIA on 7.0-Tesla MRI has been investigated 9 . The investigators focused on differences between 1-week and 2-month images in the detection of the presence of lesions or changes in their enhancement patterns. However, no information is available regarding the natural course of plaque enhancement occurring at more than 2 months after the onset of cerebral ischemic stroke. The purpose of our study is to investigate whether contrast-enhanced high-resolution MRI can be used to determine longer time course changes in symptomatic MCA plaques.
Methods

Patients
This study was approved by the institutional ethics committee, and informed consent was obtained from every patient. The study was based on data clinically ob- We considered the following ischemic stroke risk factors: age, sex, hypertension, hyperlipidemia, diabetes, premedication with statins, coronary vascular disease, ischemic stroke or TIA history, atrial fibrillation, and history of smoking tobacco. We administered an antiplatelet agent and rosuvastatin to all 7 patients. In every patient, we administered 100 mg of aspirin. 
Magnetic Resonance Imaging
Cross
Image Analysis
The images were reviewed by an independent neurologist (M.H-A.), who was blinded to the patients' clinical information, with the aid of a neuroradiologist who had 10 years experience (T.S.). The T1 images obtained before and after contrast injection with 3D LOWRAT were magnified up to 300%, and the regions of interest were set at the MCA stenotic and thalamic sites to measure signal intensity (SI), as previously described by Kanda et al. 13 . Regions of interest were drawn as in Figure 1 A and D normal is B 10 (Fig. 2) .
Results
We studied the 7 patients (Table 1) , who were all found to have focal enhancement at the stenotic region ( Fig. 3   and 4) . The enhancement after follow-up decreased in 4 patients ( Fig. 3) , while no such decrease was seen in the other 3 patients (Fig. 4) . Only 1 of the 4 patients, whose focal enhancement decreased, showed improvement in M1 stenosis (Fig. 5) , whereas no such improvement was found in 3 patients. Two of the 3 patients without focal enhancement had recurrence of ischemic stroke, while the other patient had no further ischemic stroke.
Discussion
In our study, all 7 patients with symptomatic M1 stenosis had focal enhancement, which we considered to be due to the presence of unstable plaques 14 (Fig. 3) . Focal enhancements are reduced. Fig. 4 Contrast-enhanced MR images at the initial stage and follow-up stage are shown for 3 patients, as in Figure 3 . Arrows indicate focal enhancement at the M1 segment of the middle cerebral artery (MCA) stenotic region. Graphs on the right are the contrast ratios at the initial and follow-up stages. Focal enhancements are not reduced. with symptomatic M1 segment stenosis at 1 month after disease onset, but this effect decreased at 7 months after.
Our observation of the change in focal enhancement was higher than the data reported by van der Kolk et al. 7 (57% vs. 29%); there were differences in terms of numbers of patients (7 vs. 28), observation period (7 vs. 2 months), and MRI (3-vs. 7-Tesla).
In the present study, we observed focal enhancement reduction in 4 of 7 patients, while the other 3 patients showed no reduction. In 2 of those 3 patients, ischemic stroke recurrence occurred (patients F and G in Fig. 4) .
The patients experienced more recurrences due to the extended follow up period. MRA showed that stenosis improved in only 1 of the 4 patients who had attenuated plaque enhancement. A possible reason is that positive remodeling had already taken place in the artery and also that stenosis seemed to improve in association with plaque reduction 16, 17 . No definitive information is available to confirm this. Despite this limitation, our finding may be noteworthy enough to add prospective data in the near future.
The current study has some additional limitations.
First, we scanned our patients retrospectively. The lack of comparison between patients with asymptomatic and symptomatic MCA plaques is another limitation. Furthermore, one of our reviewers was a neurologist, not a neuroradiologist. Since patients with stenosis less than 70% were excluded, selection bias may have had an effect on our results. Our study suggests that longer follow-up periods may lead to more changes in Gdcontrast enhancement at the site of high-grade stenosis.
Our findings may contribute to the understanding of the natural development of symptomatic MCA stenosis and may influence clinical evaluation as well as improve recurrence prediction. One patient had a decrease in plaque enhancement and consequent improvement of stenosis. This suggests that the reduction of intracranial artery plaques may be accurately observed by contrastenhanced high-resolution 3T-MR images, although further studies with a prospective design, enrolling more patients, evaluated over a period of 6 months or longer will be required.
